

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited **翰森製藥集團有限公司**

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

EXCLUSIVE LICENSING AND CO-DEVELOPMENT AGREEMENT WITH GHDDI

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**”) is pleased to announce that Hansoh (Shanghai) Healthtech Company Ltd.* (翰森(上海)健康科技有限公司) (the “**Licensee**”), a wholly-owned subsidiary of the Company, recently entered into an exclusive licensing and co-development agreement (the “**Licensing Agreement**”) with Beijing Huayi Health Drug Discovery Institute* (北京華益健康藥物研究中心) (also known as the Global Health Drug Discovery Institute, (“**GHDDI**”)).

Pursuant to the Licensing Agreement, the Licensee was granted exclusive worldwide rights to develop, manufacture and commercialize the anti-novel coronavirus (“**SARS-CoV-2**”) new drug candidate GDI-4405 series (the “**Candidate**”). The Licensee will pay a RMB12 million upfront payment and potential payments upon reaching development, regulatory and sales-based commercial milestones of up to RMB1,680 million, plus tiered royalties on future net sales.

ABOUT THE CANDIDATE GDI-4405 SERIES

The Candidate is an oral small molecule SARS-CoV-2 3CL (3C-like) protease inhibitor. The Candidate exhibits high potent antiviral activity on SARS-CoV-2 delta and omicron variants.

ABOUT GHDDI

Established in Beijing in 2016, GHDDI is an independent, not-for-profit new drug discovery and development organization jointly founded by the Bill & Melinda Gates Foundation, Tsinghua University and the Beijing Municipal Government.

The Company cannot guarantee that it will be able to successfully develop and ultimately market the Candidate. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, August 22, 2022

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Mr. Lyu Aifeng and Miss Sun Yuan as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai and Ms. Yang Dongtao as independent non-executive directors.

* *For identification purposes only*